Instruct ADDREES ADDREES WARDERS Instruction of the UNION of the Stormal Products Stoneham, NA 02180 Z/6/2018* (781) 597-7500 Fax: (781) 587-7556 3004483427 Instruct ADDREES PRODUCT FORMER PROFESSION 3004483427 Instruct ADDREES Products Instruct ADDREESSION Instruct ADDREES Product For ADDREESSION Instruct ADDREESSION Instruct ADDREESSION	DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION								
Stoneham, MA 02180 (781)597-7500 Fax: (781)587-7556 THEMAMARE 3004483427 HMAR AND OWLEY INVERSE HILL PLANTAGE STREET ADDRESS UNAIL PLANTAGE Lynnfield Drug, Inc. dba Freedom Pertility Pharmacy (IV, MAR, 2000, CONTR) STREET ADDRESS IV PRESENTANCE Byfield, MA 01922-1221 Producer of Non-Sterile and Sterile Products This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection of your facility. They are inspectional observations, place contact FDA at the phone number and address above. If you have an objection regarding an observation, place contact FDA at the phone number and address above. DURING AN INSPECTION OF YOUR FIRM 108SERVED: OBSERVATION 1 Disinfecting agents and cleaning pads and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile. Specifically, your firm cleans the interior of the ISO-5 classified (b) (4) wipes) to perform this cleaning process. There has been no assessment related to the use of non-sterile wipes in the ISO-5 classified area where aseptic processing occurs. OBSERVATION 2 You had inadequate HEPA filter airflow over the area to which sterile product was exposed. Specifically, on April 12, 2017, your firm performed an air pattern analysis (smoke study) of the sterile cleanroom suite and ISO-5 classified areas. The smoke studies conducted within the ISO-5 classified		R	DATE(S) OF I						
Sconeral Processing 3004483427 Image: Store Table Store Table Store St									
Hilary Thibault, Pharmacist in Charge Iwnswer Interfacements Lynnfield Drug, Inc. dba Freedom 12 Kent Way, Suite 120F Pertility Pharmacy Interfacements GWRMME.produce could Producer of Non-Sterile and Sterile Products Producer of Non-Sterile and Sterile Products Producer of Non-Sterile and Sterile Observation, and do not represent afinal Agency determination regarding your compliance. If you have an objection regarding an observation, on have implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above. DURING AN INSPECTION OF YOUR FIRM I OBSERVED: OBSERVATION 1 Disinfecting agents and cleaning pads and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile. Iocated Specifically, your firm cleans the interior of the ISO-5 classified (b) (4) wipes) to perform this cleaning process. There has been no assessment related to the use of non-sterile wipes in the ISO-5 classified area where aseptic processing occurs. OBSERVATION 2 You had inadequate HEPA filter airflow over the area to which sterile product was exposed. Specifically, on April 12, 2017, your firm performed an air pattern analysis (smoke study) of the sterile cleanroom suite and ISO-5 classified areas. The smoke studie				33427					
THE FACE ADDRESS Lynnfield Drug, Inc. dba Freedom Pertility Pharmacy CHY, SHR, JP CORE COMING Byfield, MA 01922-1221 This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above. DURING AN INSPECTION OF YOUR FIRM I OBSERVED: OBSERVATION 1 Disinfecting agents and cleaning pads and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile. Specifically, your firm cleans the interior of the ISO-5 classified (b) (4) within your sterile cleanroom suite using (b) (4) within your sterile clean on submit related to the use of non-sterile wipes in the ISO-5 classified area where aseptic processing occurs. OBSERVATION 2 You had inadequate HEPA filter airflow over the area to which sterile product was exposed. Specifically, on April 12, 2017, your firm performed an air pattern analysis (smoke study) of the sterile cleanroom suite and ISO-5 classified areas. The smoke studies conducted within the ISO-5 classified <th>NAME AND TITLE OF INDIVIDUAL TO WHO</th> <th>DM REPORT ISSUED</th> <th>in the second second</th> <th></th> <th></th>	NAME AND TITLE OF INDIVIDUAL TO WHO	DM REPORT ISSUED	in the second						
Lynnfield Drug, Inc. dba Freedom 12 Kent Way, Suite 120F Pertility Pharmacy Inc. dba Freedom Byfield, MA 01922-1221 Inc. dba enc. dc. dc. dc. dc. dc. dc. dc. dc. dc. d	사람은 말을 수 있다. 그는 것은 것은 사람은 사람은 것 이상은 것은 것을 수 있는 것은 것을 수 있다. 것은 것을 것 같은 것을 하는 것은 것을 수 있는 것을 수 있는 것을 수 있다. 것을 수 있는 것을 것을 수 있는 것을 것을 수 있는 것을 수 있는 것을 수 있는 것을 수 있다. 것을								
Fortility Pharmacy Investment detected Byfield, MA 01922-1221 Producer of Non-Sterile and Sterile Producer of Non-Sterile and Sterile Producers This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plant in implement, corrective action in response to an observation. You may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above. DURING AN INSPECTION OF YOUR FIRM OBSERVED: OBSERVATION 1 Disinfecting agents and cleaning pads and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile. Specifically, your firm cleans the interior of the ISO-5 classified (b) (4) <th>1000</th> <th>un dhe Freeder</th> <td></td> <td>ita 1200</td> <td></td>	1000	un dhe Freeder		ita 1200					
Byfield, MA 01922-1221 Producer of Non-Sterile and Sterile Products This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plant to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above. DURING AN INSPECTION OF YOUR FIRM 1 OBSERVED: OBSERVATION 1 Disinfecting agents and cleaning pads and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile. . . Specifically, your firm cleans the interior of the ISO-5 classified (b) (4) . <td< th=""><th></th><td colspan="4">2016 - 2018년 5월에 대한 방법 2017년 2018년 2018년 2018년 2017년 2017</td></td<>		2016 - 2018년 5월에 대한 방법 2017년 2018년 2018년 2018년 2017년 2017							
Products This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or aubmit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above. DURING AN INSPECTION OF YOUR FIRM 1 OBSERVED: OBSERVATION 1 Disinfecting agents and cleaning pads and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile. Specifically, your firm cleans the interior of the ISO-5 classified (b) (4) In your sterile clean on suite using (b) (4) products. Your firm uses non-sterile wipes (b) (4) wipes) to perform this cleaning process. There has been no assessment related to the use of non-sterile wipes in the ISO-5 classified area where aseptic processing occurs. OBSERVATION 2 You had inadequate HEPA filter airflow over the area to which sterile product was exposed. Specifically, on April 12, 2017, your firm performed an air pattern analysis (smoke study) of the sterile cleanroom suite and ISO-5 classified areas. The smoke studies conducted within the ISO-5 classified									
observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above. DURING AN INSPECTION OF YOUR FIRM I OBSERVED: OBSERVATION 1 Disinfecting agents and cleaning pads and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile. Specifically, your firm cleans the interior of the ISO-5 classified (b) (4) within your sterile cleanroom suite using (b) (4) prior to the aseptic production of drug products. Your firm uses non-sterile wipes (b) (4) cleaning process. There has been no assessment related to the use of non-sterile wipes in the ISO-5 classified area where aseptic processing occurs. OBSERVATION 2 You had inadequate HEPA filter airflow over the area to which sterile product was exposed. Specifically, on April 12, 2017, your firm performed an air pattern analysis (smoke study) of the sterile cleanroom suite and ISO-5 classified areas. The smoke studies conducted within the ISO-5 classified areas. The ISO-5 classified areas. The smoke studies conducted within the ISO-5 classified	Byfield, MA 01922	2-1221							
OBSERVATION 1 Disinfecting agents and cleaning pads and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile. Specifically, your firm cleans the interior of the ISO-5 classified (b) (4) prior to the aseptic production of drug products. Your firm uses non-sterile wipes (b) (4) products. Your firm uses non-sterile wipes (b) (4) within process. There has been no assessment related to the use of non-sterile wipes in the ISO-5 classified area where aseptic processing occurs. OBSERVATION 2 You had inadequate HEPA filter airflow over the area to which sterile product was exposed. Specifically, on April 12, 2017, your firm performed an air pattern analysis (smoke study) of the sterile cleanroom suite and ISO-5 classified areas. The smoke studies conducted within the ISO-5 classified	observations, and do not rep observation, or have implen action with the FDA represe	present a final Agency determination re- nented, or plan to implement, corrective entative(s) during the inspection or sub	garding your compliance. If e action in response to an ob mit this information to FDA	you have an objection re servation, you may discu	garding an iss the objection or				
areas were not sterile. Specifically, your firm cleans the interior of the ISO-5 classified (b) (4) located within your sterile cleanroom suite using (b) (4) prior to the aseptic production of drug products. Your firm uses non-sterile wipes (b) (4) wipes) to perform this cleaning process. There has been no assessment related to the use of non-sterile wipes in the ISO-5 classified area where aseptic processing occurs. OBSERVATION 2 You had inadequate HEPA filter airflow over the area to which sterile product was exposed. Specifically, on April 12, 2017, your firm performed an air pattern analysis (smoke study) of the sterile cleanroom suite and ISO-5 classified areas. The smoke studies conducted within the ISO-5 classified		DF YOUR FIRM I OBSERVED:							
areas were not sterile. Specifically, your firm cleans the interior of the ISO-5 classified (b) (4) located within your sterile cleanroom suite using (b) (4) prior to the aseptic production of drug products. Your firm uses non-sterile wipes (b) (4) wipes) to perform this cleaning process. There has been no assessment related to the use of non-sterile wipes in the ISO-5 classified area where aseptic processing occurs. OBSERVATION 2 You had inadequate HEPA filter airflow over the area to which sterile product was exposed. Specifically, on April 12, 2017, your firm performed an air pattern analysis (smoke study) of the sterile cleanroom suite and ISO-5 classified areas. The smoke studies conducted within the ISO-5 classified	Disinfecting agents a	nd cleaning pads and cleanin	g wipes used in the I	SO 5 classified ase	ptic processing				
within your sterile cleanroom suite using (b) (4) prior to the aseptic production of drug products. Your firm uses non-sterile wipes (b) (4) wipes) to perform this cleaning process. There has been no assessment related to the use of non-sterile wipes in the ISO-5 classified area where aseptic processing occurs.	Construction and the second				• • • • • • • • • • • • • • • • • • •				
within your sterile cleanroom suite using (b) (4) prior to the aseptic production of drug products. Your firm uses non-sterile wipes (b) (4) wipes) to perform this cleaning process. There has been no assessment related to the use of non-sterile wipes in the ISO-5 classified area where aseptic processing occurs.									
within your sterile cleanroom suite using (b) (4) prior to the aseptic production of drug products. Your firm uses non-sterile wipes (b) (4) wipes) to perform this cleaning process. There has been no assessment related to the use of non-sterile wipes in the ISO-5 classified area where aseptic processing occurs.	. t.								
You had inadequate HEPA filter airflow over the area to which sterile product was exposed. Specifically, on April 12, 2017, your firm performed an air pattern analysis (smoke study) of the sterile cleanroom suite and ISO-5 classified areas. The smoke studies conducted within the ISO-5 classified	within your sterile cloproducts. Your firm cleaning process. The	eanroom suite using(b) (4 uses non-sterile wipes(b) (4 ere has been no assessment r) prior to th 4)	wipes) to perfor	on of drug m this				
You had inadequate HEPA filter airflow over the area to which sterile product was exposed. Specifically, on April 12, 2017, your firm performed an air pattern analysis (smoke study) of the sterile cleanroom suite and ISO-5 classified areas. The smoke studies conducted within the ISO-5 classified	OBSERVATION 2								
cleanroom suite and ISO-5 classified areas. The smoke studies conducted within the ISO-5 classified		HEPA filter airflow over the	area to which sterile j	product was expose	ed.				
	cleanroom suite and ISO-5 classified areas. The smoke studies conducted within the ISO-5 classified								
EMPLOYEE(S) SIGNATURE DATE ISSUED	a la campione de las de las estas en estas en entre en estas de la composition de la compositio			I					
SEE REVERSE OF THIS PAGE John P Mistler, Investigator John P Mistler, 2/27/2018 John P Mistler, Investigator John P Mistler, 2/27/2018 2/27/2018 John P Mistler, Investigator John P Mistler, 2/27/2018 2/27/2018	그는 것 같아, 영양가 영문 전쟁이 있는 것 같아. 말 것 같아. 말 집에 집에 가지 않는 것이 같아. 것 같아. 말 ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?	n P Mistler, Investigato	br		2/2//2018				
FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS PAGE 1 OF 2 PAGES	FORM FD4 483 (09/08)	PREVIOUS EDITION OBSOLETE IN	SPECTIONAL OBSERVAT	IONS	PAGE 1 OF 2 PAGES				

		FOOD AND DRUG ADM			Statum (Statum)
DISTRICT ADDRESS AND PHO One Montvale			DATE(S) OF I	NSPECTION 018-2/27/2018*	
Stoneham, MA		ł	FEI NUMBER 30044		
NAME AND TITLE OF INDIVIDU	JAL TO WHOM REPORT ISSUED		1		
Hilary Thiba	ult, Pharmacist in		ET ADDRESS		
Lynnfield Dr Fertility Ph	ug, Inc. dba Freedo armacy	107-2537	Kent Way, S	uite 120F	
CITY, STATE, ZIP CODE, COUR Byfield, MA	NTRY	Pr	TYPE ESTABLISHMENT INSPECTED Producer of Non-Sterile and Sterile Products		
	e smoke studies did not d areas, transfer of in-pr iner closure.				asfer of produc
2/06/2018(Tue)), 2/08/2018(Thu), 2/09/	2018(Fri), 2/12/2	2018(Mon), 2/1	5/2018(1ue), 2/15/	2018(1nu),
것의 것같은 잘 다 다 많은 것은 것이 많은 것이 없는 것이 같이 했다.	l), 2/27/2018(Tue)				
그는 것같은 한 다 다 많은 것이 같이 다. 것을 생각하는 것이 같이 많이 했다.	ł), 2/27/2018(Tue)				
그는 것같은 한 다 다 많은 것이 같이 다. 것을 생각하는 것이 같이 많이 했다.	ł), 2/27/2018(Tue)				
그는 것같은 한 다 다 많은 것이 같이 다. 것을 생각하는 것이 같이 많이 했다.	ł), 2/27/2018(Tue)				
그가 맛집안 다 다 다 걸 때 집에 다 갔다. 것이 없는 것이 같아.	ł), 2/27/2018(Tue)				
것의 것같은 잘 다 다 많은 것은 것이 많은 것이 없는 것이 같이 했다.	ł), 2/27/2018(Tue)				
그가 맛집안 다 다 다 걸 때 집에 다 갔다. 것이 없는 것이 같아.	ł), 2/27/2018(Tue)				
그가 맛집안 다 다 다 걸 때 집에 다 갔다. 것이 없는 것이 같아.	ł), 2/27/2018(Tue)		×		
그가 맛집안 다 다 다 걸 때 집에 다 갔다. 것이 없는 것이 같아.	ł), 2/27/2018(Tue)		x		
것의 것같은 잘 다 다 많은 것은 것이 많은 것이 없는 것이 같이 했다.	ł), 2/27/2018(Tue)		x		
것의 것같은 잘 다 다 많은 것은 것이 많은 것이 없는 것이 같이 했다.	H), 2/27/2018(Tue) EMPLOYEE(S) SIGNATURE John P Mistler, In	vestigator	2	John D Matter Investigater Signed By: 2001042085 Date Signed: 02-27-2018 06:44:55	DATE ISSUED 2/27/2018